Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 2/20/19 (What's New)

Summary

  • The phase III STARTMRK trial compared raltegravir with efavirenz, both with emtricitabine/tenofovir DF, in 563 treatment-naive patients
  • At Week 48, the efficacy of raltegravir was noninferior to that of efavirenz, with 86% and 82%, respectively, achieving HIV-1 RNA < 50 copies/mL by intent-to-treat, noncompleter-equals-failure analysis[Lennox 2009]
  • At Week 240, raltegravir was superior to efavirenz with 71% and 61% of patients, respectively, achieving HIV-1 RNA < 50 copies/mL

    Action required